Hinweise zum Coronavirus
Das UKB hat hier für Bürger*innen, Patient*innen und Gesundheitspersonal wichtige Informationen zum Coronavirus/SARS-CoV-2/COVID-19 zusammengestellt. ...weiterlesen

AG Feldmann

Principle Investigator: Dr. Georg Feldmann

Field of Interest

Pancreatic cancer is one of the most dismal of human malignancies to date and is responsible for more than 200,000 cancer-related deaths every year.

Despite considerable research efforts over the past decades, the overall prognosis of pancreatic cancer has hardly improved and remains to be among the worst of all human cancers, with an overall 5-year survival rate of less than 5% and median survival of less than 6 months after diagnosis. (For more detailed information see seer.cancer.gov or http://pathology.jhu.edu/pancreas.)



(Figure from Sharpless and DePinho, Nat Rev Drug Discov. 2006 Sep;5(9):741-54)

The number one aim of our lab is to identify novel therapeutic targets and to develop new experimental therapeutic strategies against this disease, as well as to help translate these approaches into clinical application. For this end we are applying several experimental techniques which include in vitro testing using cell culture techniques as well as in vivo studies using xenograft and genetically engineered mouse models of pancreatic cancer.

To further boost the speed and efficiency of our work we are trying to collaborate with several expert partners working in the same field in Germany as well as abroad.

(Figure from Tuveson et al., Gastroenterology 2012; 142(5):1079-92)

(Figure from Foss C et al., Mol Imaging 2007; 6(2):131-9)

Lab Members
Georg Feldmann, MD
Phone: +49-228-287-17050
E-mail: georg.feldmann@uni-bonn.de
Georg Feldmann is head of the Pancreatic Cancer Translational Research Lab. He obtained his MD degree from the University of Essen and subsequently worked as assistant physician in Prof. Sauerbruch’s Department of Internal Medicine 1 at the University Hospital of Bonn under the guidance of Prof. Spengler for two years. From 2005 to 2009 he worked as postdoctoral research fellow in Dr. Anirban Maitra’s lab at the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins University, Baltimore, Maryland, USA. Georg Feldmann returned to Germany in 2009 and joined Prof. Brossart’s Department of Internal Medicine 3 at the Center of Integrated Oncology (CIO) Cologne-Bonn, University Hospital of Bonn, where he started the Pancreatic Cancer Translational Research Lab.
Savita Bisht, PhD
E-mail: bishtsavita@gmail.com
Dr. Bisht received her PhD in chemistry from the University of New Delhi, India. She is a distinguished expert in nanoparticle-based vaccination strategies and drug delivery as well as in translational pancreatic cancer research. After completing her PhD program in India, Dr. Bisht spent a three and a half-years postdoctoral fellowship in Prof. Anirban Maitra’s group at the Sol Goldman Pancreatic Cancer Research Center of the Johns Hopkins Medical Institutions in Baltimore, MD, USA, before joining the pancreatic cancer translational research lab at the Department of Internal Medicine 3, University Hospital of Bonn in Germany.
Ute Schütte
E-mail: ute.schuette@uni-bonn.de
Ute Schütte pursued her studies in pharmacy at the universities of Münster and Lille (France) and received her degree in pharmacy in 2009. During a research fellowship at Dr. Markus Frank’s laboratory at the Children’s Hospital in Boston she discovered her interest in translational cancer research and subsequently joined our lab as a PhD student in August 2009. Her project focuses on the role of the Hippo-pathway – an embryonic signalling pathway aberrantly reactivated in several human cancers – in etiology and progression of pancreatic ductal adenocarcinomas.
Jens Haarmann
E-mail: jens.haarmann@gmx.de
Jens Haarmann studied Biology at the University of Bonn and joined our lab as a PhD student in August 2011. In his project he investigates the inhibition of the cycline dependent kinase 5 (CDK5) as a possible treatment of pancreatic ductal adenocarcinomas. The CDK5 - in contrast to normal cells of the pancreas - is often activated in pancreatic cancer and seems to play an important role for the development of metastases.
Miriam Menger
E-mail: miriam.menger@gmx.net
Miriam Menger received her Bachelor's degree in Applied Biology from Bonn-Rhine-Sieg University of Applied Sciences. Afterwards she came to the Feldmann group as a student research assistant and started in parallel studying the Master course Biomedical Sciences. As a student research assistant she is at the moment responsible for genotyping of mice.
Kirsten Sadler
E-mail: kirsten.sadler@ukb.uni-bonn.de
Kirsten Sadler is working as secretary in the office of AG Feldmann Lab. If there are any requests, here her office hours: Monday, Wednesday, Friday from 8:30 h to 13:30 h.

Phone number: +49 (0)228 287 51600.

Dhriti Dhawan
E-mail: dhawandhriti@ymail.com
Dhriti Dhawan is a student at the University of Bonn where she is pursuing her master’s in Molecular Biotechnology. She has completed her Bachelors in Biochemistry from the University of Delhi. She has worked in AG Feldmann Lab on the renal cell carcinoma cell lines; observing the effects of different drugs- namely curcumin, sorafenib and EF24, on these cell lines. Moreover, as a part of her master thesis she would determine the effect of a new drug on the Axl receptor tyrosine kinase. It has been proved that the overexpression of this receptor tyrosine kinase has an adverse prognostic influence in pancreatic cancer by promoting tumor cell invasion and survival in pancreatic ductal adenocarcinoma. She hopes to perform some constructive work in this field and determine some therapeutic applications for the same. Currently she is working as a PhD student at Max-Delbrück-Centrum für Molekulare Medizin in Berlin.

The pancreatic cancer translational research lab at work...... and after work (annual meeting of the department at castle Engers 2011).

List of Publications

Collaboration Partners

Anirban Maitra, MBBS
Associate Professor of Pathology, Oncology, and Chemical and Biomolecular Engineering Affiliate, McKusick-Nathans Institute of Genetic Medicine
The Sol Goldman Pancreatic Cancer Research Center
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Barry D. Nelkin, PhD
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

PD Dr. med. Volker Fendrich
Oberarzt der Klinik für Visceral-, Thorax- und Gefäßchirurgie der Philipps-Universität Marburg

Alessio Nencioni, MD
Università degli Studi di Genova, Italy

Dr. Lukas Heukamp, Prof. Dr. Reinhard Büttner
Centrum für Intergrierte Onkologie (CIO) Köln–Bonn
Institut für Pathologie
Rheinische Friedrich–Wilhelms–Universität Bonn

Prof. Dr. Jacob Nattermann, Prof. Dr. Ulrich Spengler
Medizinische Klinik 1
Rheinische Friedrich–Wilhelms–Universität Bonn

Surajit Dhara, PhD
National Institute of Biomedical Genomics (NIBMG)
Kalyani, West Bengal, India





Center of Integrated Oncology Cologne-Bonn und dessen Zentrum für Integrierte Onkologie Köln Bonn: